OPPM
CLVS

Opus Point Partners Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Opus Point Partners Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-82,430
Closed -$2.42M – 46
2018
Q3 		$2.42M Buy
82,430
+69,430
+534% +$2.69M 5.78% 3
2018
Q2 		$591K Hold
13,000
– – 1.28% 24
2018
Q1 		$686K Sell
13,000
-2,000
-13% -$117K 1.35% 25
2017
Q4 		$1.02M Hold
15,000
– – 0.88% 33
2017
Q3 		$1.24M Hold
15,000
– – 1.11% 32
2017
Q2 		$1.4M Sell
15,000
-15,000
-50% -$918K 1.29% 31
2017
Q1 		$1.91M Hold
30,000
– – 1.42% 29
2016
Q4 		$1.33M Buy
+30,000
New +$1.06M 1.06% 30
2016
Q2 		– Sell
-75,000
Closed -$1.44M – 53
2016
Q1 		$1.44M Buy
75,000
+25,000
+50% +$529K 1.11% 28
2015
Q4 		$1.75M Sell
50,000
-8,567
-15% -$552K 1.16% 26
2015
Q3 		$5.39M Buy
58,567
+6,167
+12% +$534K 2.97% 3
2015
Q2 		$4.61M Sell
52,400
-3,588
-6% -$307K 3.65% 6
2015
Q1 		$4.16M Buy
55,988
+28,988
+107% +$2.05M 3.48% 2
2014
Q4 		$1.51M Buy
+27,000
New +$1.42M 1.5% 26

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Opus Point Partners Management's CLVS Position: Q4 2018 in Review

Opus Point Partners Management sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 82,430 shares — an estimated $2.42M sold.

Opus Point Partners Management first reported a position in CLVS in Q4 2014 and held it in 14 quarters. The position peaked at $5.39M in Q3 2015. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Opus Point Partners Management reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Opus Point Partners Management sold 82,430 Clovis Oncology, Inc. shares in Q4 2018, an estimated $2.42M.
  • Opus Point Partners Management first reported a position in Clovis Oncology, Inc. in Q4 2014 and held it in 14 quarters.
  • Opus Point Partners Management's Clovis Oncology, Inc. position peaked at $5.39M in Q3 2015.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Opus Point Partners Management's 13F filing for Q4 2018, filed 14 Feb 2019.